Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Olysio

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olysio was produced by Janssen.

Olysio drives J&J pharma sales

Olysio drives J&J pharma sales Johnson &Johnson (J&J) has raised its earnings forecasts for the year based on surging pharma sales driven mainly by new hepatitis C drug Olysio. ... Morningstar analyst Damien Conover believes Olysio sales will drop by around 50% next year in the face

SMC recommends Novartis’ Gilenya for severe form of MS

SMC recommends Novartis’ Gilenya for severe form of MS Janssen continued to expand its hepatitis C business with a recommendation for Olysio (simeprevir), while both Takeda and MSD received two recommendations each.

Gilead gets US approval for Sovaldi follow-up Harvoni

Gilead gets US approval for Sovaldi follow-up Harvoni recently approved Olysio (simeprevir), the new drug promises to "change the treatment paradigm for Americans living with the disease.".

Gilead’s hep C combination Harvoni recommended for EU approval

Gilead’s hep C combination Harvoni recommended for EU approval Over the past few months, the CHMP has recommended marketing authorisations for three other medicines for the treatment of HCV - Sovaldi, J&J's Olysio and BMS' Daklinza.

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance Janssen has released a statement saying they are 'extremely disappointed' with NICE's decision to recommend Olysio (simeprevir) for only one out of three of its licenced indications for hepatitis C. ... NICE also recommends that clinical data, including

[ Previous 5 results ] 1 2 3 4 5 6 7 8 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....